🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the battle against drug-resistant strains of the infection, according to researchers.

An International Health Concern

Gonorrhoea infections are on the rise globally, with estimates suggesting more than 82 million new cases per year. Notably increased rates are reported in the African continent and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to significant complications, including infertility. Researchers believe that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in the same week. This drug, which is employed against UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Testing Data and Worldwide Availability

As per data published in a major medical journal, the new drug eradicated the vast majority of genital gonorrhoea infections. This places it at an similar efficacy with the current standard treatment, which combines a dual-drug approach. The study enrolled over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have voiced hope. Having a single-dose, oral treatment of this kind is described as a "critical tool" for managing the epidemic. This is considered vital to reduce the burden of the disease for people and to prevent the spread of highly drug-resistant gonorrhoea globally.